Literature DB >> 1426258

Primary structure required for the inhibition of smooth muscle myosin light chain kinase.

M Ikebe1, S Reardon, F S Fay.   

Abstract

Myosin light chain kinase (MLCK) contains the autoinhibitor sequence right next to the N-terminus side of the calmodulin binding region. In this paper, the structural requirement of the inhibition of MLCK activity was studied using synthetic peptide analogs. Peptides Ala-783-Lys-799 and Ala-783-Arg-798 inhibited calmodulin independent MLCK at the same potency as the peptide Ala-783-Gly-804. Deletion of Arg-797-Lys-799 or substitution of these residues to Ala markedly increased the Ki while the substitution of Lys-792 and Lys-793 to Ala and the deletion of Lys-784-Lys-785 did not affect the inhibitory activity of the peptides. The results suggest that Arg-797-Arg-798 are especially important for the inhibitory activity among other basic residues in the autoinhibitory region.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1426258     DOI: 10.1016/0014-5793(92)80944-c

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

Review 1.  Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application.

Authors:  Jerrold R Turner
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

2.  Phosphorylation of non-muscle myosin II regulatory light chain by p21-activated kinase (gamma-PAK).

Authors:  T L Chew; R A Masaracchia; Z M Goeckeler; R B Wysolmerski
Journal:  J Muscle Res Cell Motil       Date:  1998-11       Impact factor: 2.698

Review 3.  Calmodulin and the regulation of smooth muscle contraction.

Authors:  M P Walsh
Journal:  Mol Cell Biochem       Date:  1994-06-15       Impact factor: 3.396

4.  A calcium signaling cascade essential for myosin thick filament assembly in Xenopus myocytes.

Authors:  M B Ferrari; K Ribbeck; D J Hagler; N C Spitzer
Journal:  J Cell Biol       Date:  1998-06-15       Impact factor: 10.539

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.